Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bayzed Health GroupHKSE:02609 -1.81%12 Piotroski F-Score is 6 as of Aug. 14, 2026, which is 14% below its 10-year median of 7.00. GuruFocus rates HKSE:02609 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 641 Healthcare Providers & Services companies, Bayzed Health Group ranks better than 75.04% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Bayzed Health Group has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Bayzed Health Group's Piotroski F-Score or its related term are showing as below:
HKSE:02609'
s Piotroski F-Score Range Over the Past 10 Years
Min: 6 Med: 7 Max: 8
Current: 6
During the past 5 years, the highest Piotroski F-Score of Bayzed Health Group was 8. The lowest was 6. And the median was 7.
Bayzed Health Group (HKSE:02609) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Bayzed Health Group Piotroski F-Score Related Terms
Bayzed Health Group Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Bayzed Health Group's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02609 vs HCA, THC, DVA: Piotroski F-Score Comparison
For the Medical Care Facilities subindustry, Bayzed Health Group's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayzed Health Group Piotroski F-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Bayzed Health Group's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Bayzed Health Group's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Bayzed Health Group's current Net Income (TTM) was -14.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Bayzed Health Group's return on assets of this year was -0.00608544. Bayzed Health Group's return on assets of last year was -0.00594016.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Bayzed Health Group's gearing of this year was 0.08463846. Bayzed Health Group's gearing of last year was 0.09052556.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Bayzed Health Group's current ratio of this year was 1.68525792. Bayzed Health Group's current ratio of last year was 0.96958105.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Bayzed Health Group's number of shares in issue this year was 1255.378. Bayzed Health Group's number of shares in issue last year was 1318.467.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Bayzed Health Group's gross margin of this year was 0.17039103. Bayzed Health Group's gross margin of last year was 0.17512515.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Bayzed Health Group's asset turnover of this year was 0.52594983. Bayzed Health Group's asset turnover of last year was 0.52476591.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
0
+
1
+
1
+
1
+
1
+
0
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Bayzed Health Group has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Bayzed Health Group (HKSE:02609) has a Piotroski F-Score of 6 as of Aug. 14, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bayzed Health Group and its competitors. This is 14% below median its historical median of 7.00. Over the past decade, Bayzed Health Group's Piotroski F-Score has ranged from 6.00 to 8.00. According to the industry distribution chart, Bayzed Health Group ranks #160 out of 641 companies in the Healthcare Providers & Services industry, placing it in the top 25%.
Is Bayzed Health Group's Piotroski F-Score too high?
Bayzed Health Group's current Piotroski F-Score of 6 is 14% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 8.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. Bayzed Health Group's value of 6 is 20% above this industry median. Based on the distribution chart, Bayzed Health Group ranks #160 out of 641 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Bayzed Health Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bayzed Health Group's Piotroski F-Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Bayzed Health Group ranks #160 out of 641 companies for Piotroski F-Score. This places Bayzed Health Group in the top 25% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Bayzed Health Group's value of 6 is 20% above this benchmark. Historically, Bayzed Health Group's own Piotroski F-Score has ranged from 6.00 to 8.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Bayzed Health Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 641 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayzed Health Group's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bayzed Health Group and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayzed Health Group's current Piotroski F-Score is 6, which is 14% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayzed Health Group stock overvalued right now?
Bayzed Health Group (HKSE:02609) has a current Piotroski F-Score of 6. The current Piotroski F-Score is 6, which is 14% below median its 10-year median of 7.00 and 20% above the Healthcare Providers & Services industry median of 5.00. Bayzed Health Group's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Bayzed Health Group (HKSE:02609), the current Piotroski F-Score is 6 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bayzed Health Group Inc is an oncology healthcare group that principally engages in the investment in, and provision of, medical and healthcare related services in the PRC. It operates and manages a network of eight hospitals in Beijing, Tianjin, Shanxi Province, Anhui Province, and Henan Province, with a strategic focus on the provision of full-cycle oncology healthcare services through its direct ownership of the equity interest in six private for-profit hospitals and management over two private not-for-profit hospitals.
12GF Score
Get the complete analysis for HKSE:02609
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02609 has been successfully added to your 
